Aiolos Bio

Acquired

Home | GSK

San Francisco, United States · Founded 2023 · $245.0M raised

Employees
11–50
Founded
2023
Business Model
B2B
Total Funding
$245.0M
Last Round
$245.0M Series AOct 2023
Rounds
1
Acquisition Date
Feb 2024

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Aiolos Bio was a San Francisco Bay Area-based clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment landscape for respiratory and inflammatory diseases. Founded in 2023, the company launched with a $245 million Series A financing round co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments. Its lead asset, AIO-001, is a novel long-acting monoclonal antibody targeting TSLP designed to treat asthma with twice-yearly dosing. GSK acquired Aiolos Bio in February 2024 for up to $1.4 billion including $1 billion upfront.

Summary

Aiolos Bio is a Biotech company based in San Francisco, United States, founded in 2023. It has raised $245.0M in total across 1 round, most recently a $245.0M Series A round in Oct 2023. Investors include GlaxoSmithKline, Atlas Venture and Bain Capital Life Sciences.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionFeb 2024

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Aiolos Bio on Indexed.vc
<a href="https://indexed.vc/companies/aiolos-bio"><img src="https://indexed.vc/api/badge/company/aiolos-bio" alt="Aiolos Bio on Indexed.vc" width="260" height="76" /></a>